Biomedical subjects

Keith M Skubitz

Publications and source records attributed to Keith M Skubitz.

22 records · Page 2Linked to original sources

PubMed2003

Phase II trial of pegylated-liposomal doxorubicin (Doxil) in sarcoma.

Pegylated-liposomal doxorubicin (Doxil) is a unique form of liposomal doxorubicin in which the liposomes are coated with methoxypoly (ethylene glycol), resulting in a diminished uptake by the reticuloendothelial system, leading to a longer half-life in blood and a different toxicity profile than nonpegylated liposomes. We performed a phase II study of Doxil in sarcoma. The patient population was primarily previously treated or had diagnoses considered unresponsive to chemotherapy. The initial dose per course was 55 mg/m2 every four weeks with dose modification based on mucositis and hand-foot syndrome (the main limiting toxicities). Treatment was generally well tolerated. Of 214 evaluable treatment courses in 47 patients, toxicities were mild and similar to previous reports, but dose reduction was common. No definite cardiac toxicity was observed. There were: 6 osteosarcomas, 3 Ewings, 1 extraosseous osteosarcoma, 1 chondrosarcoma, 2 alveolar soft part sarcomas, 15 gastrointestinal stromal cell tumors (GIST), and 19 other soft tissue sarcomas. Three of the 47 patients received a CR or PR, although 15 of the 47 patients were felt to have derived clinical benefit from the treatment. Some responses were delayed. These data suggest that pegylated-liposomal doxorubicin has activity in this population of poor prognosis sarcoma and that this treatment is associated with modest toxicity.

Adult↗

PubMed2002

Phase II trial of pegylated-liposomal doxorubicin (Doxil) in renal cell cancer.

Twelve patients with refractory renal cell cancer were treated on a phase II study of pegylated-liposomal doxorubicin (Doxil). The initial dose per course was 55 mg/m2 every four weeks with dose modification based on mucositis and hand-foot syndrome (the main limiting toxicities). Toxicities were mild and similar to previous reports but dose reduction per the study protocol, which was designed to control the skin and mucosal toxicities, was common. No definite cardiac toxicity was observed. No objective responses were observed in 11 evaluable patients. This study did not demonstrate activity of pegylated-liposomal doxorubicin in renal cell cancer, although it can be given with mild toxicity.

Aged↗

PubMed2002

Differential gene expression in renal-cell cancer.

Renal-cell carcinoma (RCC) is an important cause of morbidity and mortality, and its incidence has been increasing. Malignant transformation is thought to be associated with changes in the expression of several genes, and this alteration in gene expression is believed to be critical to the development of the malignant phenotype. In this study, the expression of about 60,000 genes/expressed sequence tags in clear-cell RCC, normal kidney, and a set of diseased nonmalignant kidneys was determined with the use of the Affymetrix microarray technique, and differences in gene expression were analyzed. Many genes were found to be differentially expressed in these two sample sets. The genes that were expressed greater than four times more in RCC, those expressed only in RCC, and those expressed greater than two times more in RCC and also expressed in a limited number of other tissues were analyzed for their expression in a variety of other normal and diseased tissues. Some of the genes identified were overexpressed only in RCC among the tissues examined, and some were overexpressed in several other malignant tissues in addition to RCC. Other genes were overexpressed in RCC compared with normal kidney but were also overexpressed in diseased nonmalignant kidney or a variety of other normal tissues. All of the RCC samples could be clustered together, separate from the normal and diseased kidney samples, with the use of the Eisen clustering technique and a set of 50 genes. The observed changes in gene expression in RCC should help further the understanding of the biology of RCC and may be useful in diagnosis, treatment, and imaging.

Carcinoma, Renal Cell↗

PubMed2002

Phase II trial of pegylated-liposomal doxorubicin (Doxil) in mesothelioma.

Pegylated-liposomal doxorubicin (Doxil) is a form of liposomal doxorubicin in which the liposomes are coated with methoxypoly(ethylene glycol), resulting in a diminished uptake by the reticuloendothelial system, a longer half-life in blood, and a different toxicity profile than nonpegylated liposomes. A phase II study of Doxil in mesothelioma was performed. The initial dose per course was 55 mg/m2 every 4 weeks with dose modification based on mucositis and hand-foot syndrome (the main limiting toxicities). Treatment was generally well tolerated. Of 73 evaluable treatment courses in 15 patients, toxicities were mild and similar to previous reports, but dose reduction was common. No definite cardiac toxicity was observed. Fourteen patients were evaluable for response; four of the 15 patients treated responded meaningfully. These data suggest that pegylated-liposomal doxorubicin has activity in mesothelioma, and that this treatment is associated with modest toxicity.

Adult↗